Fludarabine

DB01073

small molecule approved

Deskripsi

Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Struktur Molekul 2D

Berat 285.235
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 20 hours
Volume Distribusi -
Klirens (Clearance) * 117-145 mL/min [patients with B-cell CLL receiving IV administration of a single dose of 40 mg/m^2.

Absorpsi

Bioavailability is 55% following oral administration.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with or without food. Administration with food delays absorption, but not to a clinically significant extent.

Interaksi Obat

547 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Fludarabine.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Fludarabine.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fludarabine.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fludarabine.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fludarabine.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fludarabine.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Fludarabine.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fludarabine.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Fludarabine.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fludarabine.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Fludarabine.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fludarabine.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fludarabine.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Fludarabine.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fludarabine.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fludarabine.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Fludarabine.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Fludarabine.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Fludarabine.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fludarabine.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Fludarabine.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fludarabine.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Fludarabine.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Fludarabine.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fludarabine.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fludarabine.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Fludarabine.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fludarabine.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Fludarabine.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Fludarabine.
Cladribine Fludarabine may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Fludarabine.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Fludarabine.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Fludarabine.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Fludarabine.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fludarabine.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Fludarabine.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Fludarabine.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Fludarabine.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Fludarabine.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Fludarabine.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Fludarabine.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Fludarabine.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fludarabine.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Fludarabine.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Fludarabine.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Fludarabine.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Fludarabine.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Fludarabine.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Fludarabine.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Fludarabine.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Fludarabine.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Fludarabine.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Fludarabine.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Fludarabine.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Fludarabine.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Fludarabine.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fludarabine.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Fludarabine.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Fludarabine.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fludarabine.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fludarabine.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Fludarabine.
Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Fludarabine.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Fludarabine.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fludarabine.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Fludarabine.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Fludarabine.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Fludarabine.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Fludarabine.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Fludarabine.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Fludarabine.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Fludarabine.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fludarabine.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fludarabine.
Tretinoin The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Fludarabine.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Fludarabine.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Fludarabine.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Fludarabine.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fludarabine.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Fludarabine.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Fludarabine.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Fludarabine.
Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Fludarabine.
Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Fludarabine.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Fludarabine.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Fludarabine.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Fludarabine.
Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fludarabine.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Fludarabine.
Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Fludarabine.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Fludarabine.
Doxorubicin The risk or severity of adverse effects can be increased when Doxorubicin is combined with Fludarabine.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Fludarabine.
Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Fludarabine.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fludarabine.
Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Fludarabine.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Fludarabine.
Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Fludarabine.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Fludarabine.

Target Protein

DNA
Adenosine deaminase ADA
Deoxycytidine kinase DCK
DNA polymerase alpha catalytic subunit POLA1
Ribonucleoside-diphosphate reductase large subunit RRM1

Referensi & Sumber

Synthesis reference: John G. Bauman, Randolph C. Wirsching, "Process for the preparation of fludarabine or fludarabine phosphate from guanosine." U.S. Patent US5602246, issued January, 1992.
Artikel (PubMed)
  • PMID: 11114313
    Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000 Dec 14;343(24):1750-7.
  • PMID: 9698219
    Gonzalez H, Leblond V, Azar N, Sutton L, Gabarre J, Binet JL, Vernant JP, Dighiero G: Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther. 1998 Jun;40(3):113-8.
  • PMID: 12969985
    Tournilhac O, Cazin B, Lepretre S, Divine M, Maloum K, Delmer A, Grosbois B, Feugier P, Maloisel F, Villard F, Villemagne B, Bastit D, Belhadj K, Azar N, Michallet M, Manhes G, Travade P: Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood. 2004 Jan 1;103(1):363-5. Epub 2003 Sep 11.

Contoh Produk & Brand

Produk: 35 • International brands: 0
Produk
  • Aj-fludarabine
    Solution • 25.0 mg / mL • Intravenous • Canada • Generic • Approved
  • Fludara
    Injection, powder, lyophilized, for solution • 50 mg/2mL • Intravenous • US • Approved
  • Fludara
    Injection, powder, lyophilized, for solution • 50 mg/2mL • Intravenous • US • Approved
  • Fludara
    Tablet • 10 mg • Oral • Canada • Approved
  • Fludara
    Powder, for solution • 50 mg / vial • Intravenous • Canada • Approved
  • Fludarabine
    Injection, solution • 25 mg/1mL • Intravenous • US • Generic • Approved
  • Fludarabine
    Injection, powder, lyophilized, for solution • 25 mg/1mL • Intravenous • US • Generic • Approved
  • Fludarabine Phosphate
    Tablet, film coated • 10 mg/1 • Oral • US • Approved
Menampilkan 8 dari 35 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul